<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Baumann, Tycho</dc:creator>
  <dc:creator>Moia, Riccardo</dc:creator>
  <dc:creator>Gaidano, Gianluca</dc:creator>
  <dc:creator>Delgado, Julio</dc:creator>
  <dc:creator>Condoluci, Adalgisa</dc:creator>
  <dc:creator>Villamor, Neus</dc:creator>
  <dc:creator>Payedimarri, Anil Babu</dc:creator>
  <dc:creator>Costa, Dolors</dc:creator>
  <dc:creator>Patriarca, Andrea</dc:creator>
  <dc:creator>Jiménez-Vicente, Carlos</dc:creator>
  <dc:creator>Rossi, Davide</dc:creator>
  <dc:creator>Montserrat, Emili</dc:creator>
  <dc:date>2021-02-04</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The prognostic significance of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was identified when the biology of the  disease was poorly understood and therapy was not effective. We assessed the clinical and biological significance of LDT in 848 CLL  patients in a real-life setting and the context of new biomarkers and effective therapy. A short LDT (≤12 months) was enriched for adverse  biomarkers. Patients with a rapid LDT did need therapy shortly after diagnosis (median 23 months vs. not reached; p &lt; 0.001) and had a  poorer overall survival (median 95 months vs. not reached p &lt; 0.001). LDT, IGHV mutational status, Beta-2 microglobulin, and Rai clinical  stage were independent predictors for time to first treatment in the whole series and in Binet stage A patients. No correlation was observed  between LDT and response to chemoimmunotherapy. However, a short LDT along with age ≥65 years, high-risk FISH (del(17p), del(11q)),  unmutated IGHV, increased Beta-2 microglobulin, and TP53 mutations predicted short survival. Moreover, the prognostic significance of LDT  was independent of the CLL-IPI and the Barcelona/Brno prognostic model. LDT remains an important outcome marker in the modern CLL  era and should be incorporated into the clinical assessment and stratification of CLL patients.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1319283</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/319283</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319283/files/Rossi_2021_leukemia_AAM.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41375-021-01149-w</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319283</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Leukemia. - 2021, p. 7 p</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Lymphocyte doubling time in chronic lymphocytic leukemia modern era : a real-life study in 848 unselected patients</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
